• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Relay Therapeutics Inc (NQ: RLAY )

    8.930 -0.550 (-5.80%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,028,437
    Open 9.400
    Bid (Size) 8.330 (1)
    Ask (Size) 9.430 (1)
    Prev. Close 9.480
    Today's Range 8.860 - 9.760
    52wk Range 5.700 - 12.63
    Shares Outstanding 121,613,181
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
    To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under... 
    Via Talk Markets
    Expert Ratings For Relay Therapeutics
    Via Benzinga

    Performance

    YTD
    -24.67%
    -24.67%
    1 Month
    +29.42%
    +29.42%
    3 Month
    +51.36%
    +51.36%
    6 Month
    -10.70%
    -10.70%
    1 Year
    -26.44%
    -26.44%

    More News

    Read More
    Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
    Via Talk Markets
    Clinical-Stage BioTech Drug Stocks Declined 13% In June
    Via Talk Markets
    Largest Clinical-Stage BioTech Drug Stocks Declined 6%
    Via Talk Markets
    Expert Ratings For Relay Therapeutics
    Via Benzinga
    Key Takeaways From Relay Therapeutics Analyst Ratings
    Via Benzinga
    AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
    Via Talk Markets
    AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
    Via Talk Markets
    Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
    Via Talk Markets
    Relay Therapeutics to Participate in Upcoming Investor Conferences
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    Relay Therapeutics to Host New Program and Platform Event on June 6, 2024
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    5 Of 7 AI Categories Rose, Slightly,Over Past Week
    Via Talk Markets
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    The 7 AI Categories Declined, On Average, The First Week Of May
    Via Talk Markets
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
    Via Talk Markets
    RLAY Stock Earnings: Relay Therapeutics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
    Via Talk Markets
    Relay Therapeutics to Participate in Upcoming Investor Conferences
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    AI Surge Ending: Only One Category Was Up This Week
    Via Talk Markets
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    3 Precision Medicine Stocks That Could Benefit From the Industry’s Rise
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.